Company profile: Be Bio
1.1 - Company Overview
Company description
- Provider of engineered B cell medicines for serious genetic diseases, including BE-101 to produce active and sustained Factor IX for Hemophilia B. Offers BCMs engineered to produce highly active and sustained antitumor biologics for cancer, and BCMs designed to produce therapeutic proteins for genetic and rare diseases.
Products and services
- Engineered B Cell Medicines for genetic diseases: Cell-based BCMs developed to produce therapeutic proteins that address a range of genetic diseases by leveraging engineered B cells to deliver disease-relevant biologics
- BE-101: A custom-engineered B cell medicine producing active and sustained Factor IX for Hemophilia B treatment, enabling durable therapeutic protein production
- Engineered B Cell Medicines (BCMs) for cancer: Biologic-producing BCMs developed to generate highly active and sustained levels of antitumor biologics for cancer treatment using engineered B cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Be Bio
GT Biopharma
HQ: United States
Website
- Description: Provider of TriKE immunotherapy technology that bridges natural killer cells to cancer cells to boost anti-tumor responses. Pipeline includes GTB-3550 for CD33+ leukemias (AML, high-risk MDS), GTB-3650 using camelid nanobodies for CD33+ leukemias, and GTB-5550, GTB-4550, GTB-6550 for B7H3, PD-L1, and HER2 positive solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GT Biopharma company profile →
Bilthoven Biologicals
HQ: The Netherlands
Website
- Description: Provider of pharmaceutical products manufacturing services and vaccine/diagnostic solutions, including inactivated polio vaccine (IPV), pandemic preparedness vaccine facilities in Europe (capacity over 300 million doses annually), SIILTIBCY tuberculosis skin test, BCG for bladder cancer and TB vaccination, DTP vaccine (diphtheria, tetanus, polio), and tetanus vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bilthoven Biologicals company profile →
Morphotek
HQ: United States
Website
- Description: Provider of gene evolution-based monoclonal antibody products to treat cancer, inflammation, and infectious diseases. Offerings include RESPECT-H+L conjugation technology enabling dual payload delivery with in vivo ADC tracking, and an Eribulin ADC payload with cytotoxic effects on receptor-positive and neighboring receptor-negative tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphotek company profile →
Adicet Bio
HQ: United States
Website
- Description: Provider of first-in-class allogeneic gamma delta CAR T cell therapies for cancer, including ADI-001 targeting B-cells for B cell-mediated autoimmune diseases and B-cell non-Hodgkin’s lymphoma; ADI-270 targeting CD70 for solid tumors such as renal cell carcinoma; and an armored PSMA CAR program for metastatic castration-resistant prostate cancer. Expanded access is currently not provided.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adicet Bio company profile →
xCella Biosciences
HQ: United States
Website
- Description: Provider of antibody discovery technologies, offering a platform to screen single B cells and develop therapeutics via protein engineering. Products include the OmniAb Discovery Platform and transgenic animal systems: OmniRat, OmniMouse, OmniChicken for generating fully human antibodies; OmniFlic and OmniClic for bispecific discovery; and xPloration integrated hardware/software for high-dimensional measurement and analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full xCella Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Be Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Be Bio
2.2 - Growth funds investing in similar companies to Be Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Be Bio
4.2 - Public trading comparable groups for Be Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →